Earlier, More Thorough Conversations Eases Distress in Advanced-Stage Patients
March 28th 2019Nurses and other healthcare providers can mitigate emotional distress and improve quality of life in patients with cancer by having earlier and more thorough conversations about their care, according to a recent study conducted at the Dana-Farber Cancer Institute.
FDA Grants Ivosidenib Breakthrough Therapy Designation for AML Subset
March 27th 2019The FDA has granted a breakthrough therapy designation to the combination of ivosidenib (Tibsovo) and azacitidine for the treatment of newly diagnosed patients with IDH1-mutant acute myeloid leukemia (AML) ≥75 years old or are ineligible for intensive induction chemotherapy.
FDA Proposes Changes to Negate Mammogram Oversight
March 27th 2019The FDA announced today that it is working to update mammography regulations, expanding the amount of information that mammography facilities must give patients and healthcare professionals. In turn, this would result in more informed decision-making – especially when it comes to breast cancer diagnoses.
An Overview of Molecular Diagnosis in Kidney Cancer
March 26th 2019While there are some exciting advances coming down the pipeline, there is still much work to do when it comes to the molecular diagnosis of patients with renal cell carcinoma (RCC), explained David I. Quinn, MBBS, PhD, FRACP, FACP.
NCCN Expands Guidelines for Colorectal Cancer Treatment
March 25th 2019Wells A. Messersmith, MD, co-director of the developmental therapeutics program at the University of Colorado Cancer Center, said work in this area is needed to fill the knowledge gaps in metastatic CRC, which has a 5-year survival rate of just 11%.
Clinicians Must Address Financial Concerns With Patients
March 14th 2019Financial distress puts a major burden on patients with cancer and their families. And while there are numerous resources that nurses can share with their patients to help with co-pays and other money-related issues, they are not widely discussed.
FDA Approves Another Trastuzumab Biosimilar
March 12th 2019The FDA has granted an approval to PF-05280014 (Trazimera; trastuzumab-qyyp), a trastuzumab (Herceptin) biosimilar, to treat patients with HER2-overexpressing breast cancer as well as HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma
FDA Approves Assay to Determine Eligibility for Tecentriq in Triple-Negative Breast Cancer
March 11th 2019The FDA approved the VENTANA PD-L1 (SP142) Assay as the first companion diagnostic to aid in identifying patients with triple-negative breast cancer who are eligible for treatment with Tecentriq (atezolizumab) plus chemotherapy.
Oral Rivaroxaban Reduces VTE in Outpatient Treatment of Patients With Cancer
March 9th 2019Rivaroxaban (Xarelto) significantly lowered the incidence of venous thromboembolism (VTE) or death due to VTE during the intervention period with the agent in patients with solid tumors or lymphoma, according to results from the CASSINI trial.
FDA Approves Atezolizumab Combo for Frontline TNBC
March 8th 2019The Food and Drug Administration has granted an accelerated approval to the frontline combination of atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC)
Nurses Need a Comprehensive Approach for Hazardous Drug Handling
March 8th 2019In an interview with Oncology Nursing News, Christopher R. Friese, PhD, RN, AOCN, FAAN, discussed his study, and though the results were not what he expected, Friese still emphasized the need for proper education for oncology nurses.
A Review on Handling Hazardous Drugs
March 5th 2019When handling chemotherapy and other potentially dangerous anti-cancer drugs, there are steps that oncology nurses should take to protect themselves and their colleagues, according to a recent presscast from the American Society of Clinical Oncology (ASCO).